CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 84 enrolled
Drug / intervention
Botulinum Toxin A +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00725322
NCT00725322N/ACompleted
CompareCT.gov

Subcutaneous Botulinum Toxin for Cutaneous Allodynia

Stanford University·interventional·Posted Jul 30, 2008·Updated Oct 25, 2017

In Brief

A clinical study evaluating Botulinum Toxin A and Placebo - Saline for Pain. Completed, enrolled 84 participants across 1 site.

Detailed Summary

Superficial injection of Botulinum toxin has been advocated for cosmetic purposes but has also been reported to be helpful for some pain conditions. The investigators have observed prolonged profound analgesia following subcutaneous superficial injection of Botulinum Toxin Type A (BTA) in patients with certain types of neuropathic pain. The investigators propose to study if addition of BTA extends pain relief compared to placebo when injected subcutaneously into areas of cutaneous allodynia (the property that a normally non-noxious stimulus is perceived as painful).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPain
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJul 30, 2008
Enrollment StartDec 1, 2007
Primary CompletionMar 1, 2013
TodayJul 2, 2026
Enrollment to primary: 5.3 yearsPosted 17.9 years ago

Interventions

Botulinum Toxin Adrug

Subcutaneous injection of Botulinum Toxin Type A into the patient's scar tissue

Placebo - Salinedrug

Subcutaneous Saline injection given at site of scar neuroma